Xenytropium

Xenytropium

SCHEMBL30428452

C[N+]1(Cc2ccc(-c3ccccc3)cc2)[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)c1ccccc1)C2

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 8/20 0.71
BLM P54132 4/20 0.69
PABPC1 P11940 1/20 0.69
CYP2C19 P33261 1/20 0.68
CHRM5 P08912 6/20 0.67
CHRM1 P11229 6/20 0.67
CHRM3 P20309 5/20 0.67
CHRM4 P08173 4/20 0.67
MEN1 O00255 3/20 0.67
KMT2A Q03164 3/20 0.67
TSHR P16473 2/20 0.67
SMN1; SMN2 Q16637 2/20 0.64
CYP3A4 P08684 1/20 0.58
CYP2C9 P11712 1/20 0.58
HIF1A Q16665 1/20 0.58
HSD17B10 Q99714 1/20 0.58
KDM4E B2RXH2 1/20 0.56
LMNA P02545 1/20 0.56
POLB P06746 1/20 0.56
ADRA2C P18825 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Xenytropium SCHEMBL29361010 1.00 CHRM2 (0.71) CHRM2BLMPABPC1CYP2C19CHRM5
Xenytropium SCHEMBL29371652 0.99 BLM (0.71) CHRM2BLMPABPC1CYP2C19CHRM5
Xenytropium SCHEMBL24707 0.99 BLM (0.71) CHRM2BLMPABPC1CYP2C19CHRM5
Bromide SCHEMBL29840597 0.93 BLM (0.77) CHRM2BLMPABPC1CYP2C19CHRM5
Butropium SCHEMBL29388793 0.86 CHRM2 (0.63) CHRM2BLMPABPC1CYP2C19CHRM5
Fentonium SCHEMBL251444 0.86 CHRM2 (0.68) CHRM2BLMPABPC1CYP2C19CHRM5
Butropium SCHEMBL11561521 0.86 BLM (0.64) CHRM2BLMPABPC1CYP2C19CHRM5
Butropium SCHEMBL1650524 0.86 BLM (0.64) CHRM2BLMPABPC1CYP2C19CHRM5
Butropium SCHEMBL26023 0.86 BLM (0.64) CHRM2BLMPABPC1CYP2C19CHRM5
Butropium SCHEMBL30185784 0.86 BLM (0.64) CHRM2BLMPABPC1CYP2C19CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260097102-A1 Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors REGENERON PHARMA (US) 2026-04-09 US disclosed
US-12472241-B2 Treatment of respiratory disorders with arachidonate 15-lipoxygenase (ALOX15) inhibitors REGENERON PHARMACEUTICALS, INC. (US) 2025-11-18 US disclosed
US-20230172904-A1 COMBINATION OF AN ANTIALLERGIC AGENT WITH MUSCARINIC ANTAGONIST AND/OR DOPAMINERGIC AGONIST FOR USE IN PREVENTING/STOPPING OF AXIAL MYOPIA IN HUMAN DAMBROSIO ENZO MARIA (IT) 2023-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260097102-A1 Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors ALOX15, ALOX15B, ALOX5 CHRM2 4475/4885BLM 924/4885PABPC1 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.